Replies to post #216401 on Biotech Values

[biotech_researcher]

Ablynx rejecting an offer from NOVO that had a 66% premium?

The proposal represents a 66% premium over Ablynx's three-month volume-weighted average price of EUR18.39 as of Jan. 5, and comprises EUR28 in cash for each share plus one contingent value right with total potential cash payments over time of up to EUR2.50 a share.